During controlled clinical trials in healthy subjects, single doses of up to Januvia 800 mg were administered. Maximal mean increases in QTc of 8 msec were observed in 1 study at a dose of Januvia 800 mg, a mean effect that is not considered clinically important (see Pharmacology under Actions). There is no experience with doses >800 mg in humans.
In the event of an overdose, it is reasonable to employ the usual supportive measures, eg, remove unabsorbed material from the GI tract, employ clinical monitoring (including obtaining an electrocardiogram) and institute supportive therapy as dictated by the patient's clinical status. Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hr hemodialysis session. Prolonged hemodialysis may be considered if clinically appropriate. It is not known if sitagliptin is dialyzable by peritoneal dialysis.